Private equity firm Hillhouse Capital Management agreed to acquire a 7.5% stake in Asymchem, a Chinese pharmaceutical company, for $331m. After the deal is complete, Hillhouse will help facilitate deals between Asymchem and the innovative drug firms in which the new investor already invests or will invest in.